Description: Biocept, Inc., a cancer diagnostics company, is engaged in the development and commercialization of proprietary circulating tumor cell (CTC) and circulating tumor DNA tests. The company's tests provide information to oncologists that enable them to select the appropriate treatment for their patients based on detailed data on the characteristics of tumors. Its tests include OncoCEE-BR, a breast cancer CTC test that allows physician to characterize the tumor to help define treatment options. The company sells its products through its sales force and partners that focus on selling directly to community oncologists in hospitals, cancer centers, and offices in the United States. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
Home Page: biocept.com
BIOC Technical Analysis
9955 Mesa Rim Road
San Diego,
CA
92121
United States
Phone:
858 320 8200
Officers
| Name | Title |
|---|---|
| Mr. Samuel D. Riccitelli | Interim Pres, CEO & Chairman |
| Mr. Antonino Morales | Interim CFO & Director |
| Dr. Michael C. Dugan M.D. | Sr. VP, Chief Medical Officer & Medical Director |
| Dr. Soon Kap Hahn Ph.D. | Founder |
| Dr. Philippe J. Marchand Ph.D. | Chief Operating Officer |
| Mr. Pavel Tsinberg | Director of Technology Devel. |
| Mr. Darrell Taylor Esq. | Sr. VP, Chief Legal Officer & Chief Compliance Officer |
| Mr. David S. Moskowitz R.Ph., MBA | VP of Strategy & Corp. Communications |
| Mr. Michael Terry | Sr. VP of Corp. Devel. |
| Antonio Paternostro | VP of Sales |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3719 |
| Price-to-Sales TTM: | 0.1974 |
| IPO Date: | 2014-02-05 |
| Fiscal Year End: | December |
| Full Time Employees: | 177 |